Literature DB >> 10734296

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.

E Orsini1, E P Alyea, R Schlossman, C Canning, R J Soiffer, A Chillemi, D Neuberg, K C Anderson, J Ritz.   

Abstract

Recent reports of clinical responses following donor lymphocyte infusions (DLI) in patients with relapsed multiple myeloma (MM) after allogeneic BMT have demonstrated the ability of allogeneic cells to mediate a graft-versus-myeloma (GVM) effect, but the mechanisms involved have not been determined. To identify changes in the T cell compartment associated with DLI, we performed a molecular analysis of the T cell receptor (TCR) repertoire in four patients with relapsed MM who received infusions of CD4+ lymphocytes from HLA-identical sibling donors. Three of the four patients demonstrated a clinical anti-myeloma response following DLI but also developed graft-versus-host disease (GVHD). The TCR repertoire was examined after PCR amplification of 24 Vbeta gene subfamilies. This method determines the relative utilization of each Vbeta gene subfamily and also allows the identification of clonal and oligoclonal T cell populations through analysis of CDR3 regions for each TCR Vbeta gene subfamily. Serial blood samples were obtained over at least a 1 year period before and after DLI and results compared to 10 normal donors. Serial analysis of CDR3 size profiles demonstrated the appearance of clonal T cell populations after DLI in each of the three responding patients. The appearance of some clones was noted within the first 3 months after DLI and coincided with decreasing levels of monoclonal paraprotein indicating an ongoing GVM response. Other T cell clones appeared at later time points and coincided with the development of GVHD. These findings demonstrate that T cell clones with different patterns of onset can be identified in the peripheral blood of MM patients following DLI. Further functional characterization of these distinct clonal expansions will be required to determine whether these T cell clones are mediators of either anti-myeloma or anti-host activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734296     DOI: 10.1038/sj.bmt.1702187

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.

Authors:  Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-23       Impact factor: 5.742

2.  Age-dependent incidence, time course, and consequences of thymic renewal in adults.

Authors:  Frances T Hakim; Sarfraz A Memon; Rosemarie Cepeda; Elizabeth C Jones; Catherine K Chow; Claude Kasten-Sportes; Jeanne Odom; Barbara A Vance; Barbara L Christensen; Crystal L Mackall; Ronald E Gress
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

3.  WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Authors:  Eleanor M Tyler; Achim A Jungbluth; Richard J O'Reilly; Guenther Koehne
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

Review 4.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Limited heterogeneity of T cell receptor BV usage in aplastic anemia.

Authors:  W Zeng; J P Maciejewski; G Chen; N S Young
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

6.  Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.

Authors:  Mauro Di Ianni; Paola Olioso; Raffaella Giancola; Stella Santarone; Annalisa Natale; Gabriele Papalinetti; Ida Villanova; Stefano Baldoni; Ambra Di Tommaso; Tiziana Bonfini; Patrizia Accorsi; Paolo Di Bartolomeo
Journal:  Int J Hematol       Date:  2017-07-18       Impact factor: 2.490

7.  The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect.

Authors:  Eleanor M Tyler; Guenther Koehne
Journal:  Oncoimmunology       Date:  2013-05-15       Impact factor: 8.110

Review 8.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.